

|                         |  |
|-------------------------|--|
| Company:                | CYBERDYNE, INC.  |
| Name of Representative: | Yoshiyuki Sankai,<br>President and CEO                 |
| Code:                   | 7779 (Mothers Section of the Tokyo Stock Exchange)     |
| Contact:                | Shinji Uga, Director and CFO<br>(Tel. +81-29-869-9981) |

**HAL is now available in Taiwan**  
**~ Cyberdyne will work with CHC Healthcare Group to offer the technology to Taiwanese market~**

CYBERDYNE, INC. 【Tsukuba, Ibaraki, CEO: Yoshiyuki Sankai (“Cyberdyne”)】 announced to coordinate with CHC Healthcare Group (承業生醫企業集團), a major medical device trading company in Taiwan, to introduce HAL to Taiwan. Cyberdyne schedules to offer HAL to Yee Zen General Hospital (怡仁綜合醫院, which is a hospital owned by CHC Healthcare Group. Cyberdyne also schedules to sign a Distribution Agreement with Chiu HO Medical System Company (久和醫療儀器公司), which is a wholly owned subsidiary of CHC Healthcare Group.

CHC Healthcare Group was established in 1977 and the group has grown into a holding company of 20 subsidiaries around Taiwan and surrounding region (stock code in the Taiwanese Stock Exchange: 4164). As a major trading company of medical device, CHC Healthcare Group handles variety of medical technology from diagnostic imaging to products for neuroscience. CHC Healthcare Group operates Yee Zen General Hospital as an international institute to educate personnel with cutting-edge medical technologies. The hospital known to be the base in Taiwan for training Taiwanese medical professionals and enhancing quality of medical services.

- 1) Starting from November 2019, Cyberdyne schedules to offer 4 units of HAL Lumbar Type for Well-being (BB04) to Yee Zen General Hospital.
- 2) Cyberdyne is currently processing the application to obtain the medical device approval from Taiwan Food and Drug Administration (台灣衛生福利部食品藥物管理署, hereinafter referred to as “TFDA”) for two of Cyberdyne’s products, HAL for Medical Use Lower Limb Type and HAL Single Joint Type. As soon as Cyberdyne obtains approval from TFDA, Cybernics Treatment Center will be established within the hospital owned by CHC Healthcare Group and Cybernics Treatment will commence in Taiwan. Two companies anticipates to obtain this TFDA approval around June 2020.
- 3) After conducting Cybernics Treatment within hospital of CHC Healthcare Group for reasonable amount of time, CHC Healthcare Group will start to spread HAL to other medical institutes of Taiwan through the wholly owned subsidiary Chiu Ho Medical System Company.

CYBERDYNE will coordinate with CHC Healthcare Group to offer Cybernics Treatment to all patients in

Taiwan who is in need of this novel treatment. The two companies will make contribution to good health and well-being of the people of Taiwan.



Photo of the ceremony. On the left, Lee Pei-Lin Chairman of CHC Healthcare Group, on the right Yoshiyuki Sankai President and CEO of CYBERDYNE, INC.